Takeda and Protagonist Therapeutics have submitted a new drug application to the FDA for rusfertide for adults with ...

Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-changing power of genetic medicine to reverse or prevent blindness, today announced that dosing is complete in ...

Inuwa Ibrahim is the current managing director, Kaduna Line, overseeing Director General, Kaduna State Transport Regulatory ...

Andy Provencher spent a year searching for the cause of his exhausting symptoms before a physician's assistant suggested a ...

Curious to know which obesity stories grabbed the attention of readers this year? Medscape Medical News develops a list of ...

InflaRx to prioritize izicopan as its leading pipeline asset, with a goal of continuing toward Phase 2b readiness in ...

TEL AVIV, Israel — President Donald Trump and Israeli Prime Minister Benjamin Netanyahu are set to meet at a crucial moment ...

MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License ...

Phase 2 BESTOW trial data evaluating tegoprubart in kidney transplantation showed favorable efficacy, safety and tolerability, supporting advancement into Phase 3 development Reported positive prelimi ...

President Donald Trump has said that Venezuela is going to use funds from a new oil deal with the United States to buy "ONLY ...

The president made the remarks at a meeting with heads of oil and gas majors at the White House concerning the future of ...

Takeda & Protagonist submit NDA to US FDA seeking approval for rusfertide to treat polycythemia vera: Osaka, Japan Wednesday, January 7, 2026, 17:00 Hrs [IST] Takeda, focused on c ...